Klox understands the deep connection between people and their pets and is advancing the development and commercialization of Phovia based on its patented fluorescence biomodulation technology to address the real-world challenges faced by those who care for animals.
Phovia for companion animals and horses provides therapeutic applications in pyoderma, wound care and chronic otitis externa. Owner frustration in these skin and soft tissue diseases is often born out of lengthy treatments, frequent relapses and an increase in multidrug resistance infections, making these conditions harder to treat.
Many people are already benefiting from the Klox fluorescence biomodulation technology platform. Our objective is to bring it to animal patients in order to raise their standard of care so they can stay active and healthy.
Supporting Those Who Care for Animals
Phovia works by applying a 2-mm layer of LAM gel to to the targeted lesion area followed by a 2 minute illumination period to induce Fluorescence Biomodulation. For best results, repeat twice a week until clinical resolution.
Phovia in the Spotlight
Our comprehensive portfolio of Phovia product lines includes:
Pyoderma is defined as a bacterial infection of the skin and is a common canine disease, yet many cases are increasingly difficult to treat due to the emergence of resistant infections. Deep pyodermas will normally require systemic antibiotic treatment for 6-8 weeks, but in many cases may require additional time. The use of prolonged courses of antibiotics to treat recurring pyoderma in dogs is a risk factor for further antibiotic resistance to develop, so it is critical to research new therapeutic approaches that can accelerate clinical resolution and reduce exposure to antibiotics.
Wounds including traumatic ones are a common affliction to pets and horses. Unfortunately, the animal’s natural behavior is often detrimental to the healing process making the management of these wounds, whatever their size, laborious and often frustrating. Not infrequently, these injuries are complicated, resulting in secondary infection, dehiscence or even ulceration. In horses, these wounds are often localized in to the distal limbs, where poor circulation and joint movement can make management and healing more difficult. Chronic or complex wound management can result in long treatments (including systemic antibiotics), treatment failures and poor compliance resulting in owner dissatisfaction. Low healing rates suggest that standard care is often insufficient to promote healing of chronic wounds and wounds with large loss of substance.
Canine Chronic Otitis Externa is defined as inflammation of the external auditory canal and is one of the most common reasons for pet owners to bring their dog or cat to the vet. In dogs, it can account from 10% to 20% of primary care veterinary consultations. It is more commonly secondary to pre-existing conditions such as atopic dermatitis, and frequently becomes a chronic condition, requiring frequent veterinary visits and repeated treatment courses. If the condition continues to relapse, medical therapy can become ineffective with ablative surgery becoming a final option. One of the main aspects involved in the chronicity of the disease are infections caused by bacteria resistant to different antibiotics (e.g. Pseudomonas aeruginosa) that often create biofilms rendering antibiotic therapy less effective. With the steady rise of multi-resistant otitis cases, it is imperative to find new solutions, efficacious at breaking down biofilm and improving standard of care for these patients.
Phovia for Canine Pyoderma
- Abstract on the effects of Phovia in deep pyoderma was presented at the 29th Annual Congress of the European Society and College of Veterinary Dermatology (September, 2017). Preliminary results demonstrated that dogs that received Phovia twice weekly in conjunction with oral antibiotics (cefadroxil) achieved clinical remission in 4.3±1.3 weeks compared to 15.5±3.5 weeks for dogs receiving cefadroxil alone. The study also showed significant up-regulation of factors involved in tissue repair including, transformational growth factor-β, epidermal growth factor, neural growth factor, platelet-derived growth factor, matrix metalloproteinase 1 and 9 and increased expression of collagen lll, as well as down regulation of pro-inflammatory mediator tumor necrosis factor-α. Click here to view presented poster
- July 2, 2018: Klox announces positive top-line results from a pivotal study of Phovia™ for the management of Canine Deep Pyoderma. Phovia demonstrated efficacy for the primary endpoint, with the proportion of patients reaching clinical resolution at six (6) weeks being 26.5% for the control group and 84.6% for the Phovia treated group (p<0.001) – Click here to see Full Press Release
- Abstract on the effects of Phovia superficial pyoderma was accepted as an oral presentation at BSAVA congress (British Small Animal Veterinary Association – April, 2018). Preliminary results demonstrated that dogs that received Phovia once weekly achieved clinical remission in 2.4±1.1 weeks compared to 3.75±1.0 weeks for dogs who received oral antibiotics (cefadroxil). Click here to read abstract
- Phovia shows potential to significantly accelerate time to clinical resolution and, in cases of deep pyoderma, reduce the duration of exposure to systemic antibiotics.
The area is illuminated with a LED Activator for two (2) minutes at distance of approximately five (5) centimeters.
After the illumination is concluded, the gel is gently removed with a gauze dipped in sterile saline solution.
Phovia for Wounds
- Abstract on the effects of Phovia in cutaneous incisional wound healing in dogs was selected for oral presentation at the 27th Annual Scientific Meeting of the European College of Veterinary Surgeons (July, 2018).
Phovia for Otitis
- Abstracts on the effects of Phovia in canine chronic otitis externa were presented at the 26th European College of Veterinary Surgeons Annual Scientific Meeting (July 2017).
- Preliminary results demonstrated that Phovia applied twice a week was the most effective treatment compared to standard of care (SOC) therapy (Baytril Otic©) twice-a-day for 3 weeks as shown by a statically significant clinical score reduction at T4 and T5. Click here to view presented poster.
- Phovia shows potential to be considered a new therapeutic strategy to aid the management of chronic otitis and to possibly delay or avoid ablative surgery.
The gel is illuminated with an LED Activator for two (2) minutes with an LED that has a specially designed tip that is inserted into the ear canal.
Following the application, the canal is rinsed with sterile saline solution and massaged to remove the excess gel which is then wiped with the help of a dry gauze.